Identification of urine protein biomarkers with the potential for early detection of lung cancer
Authors:
Open Access
- 2 July 2015
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11805
Abstract
Lung cancer is the leading cause of cancer-related deaths and has an overall 5-year survival rate lower than 15%. Large-scale clinical trials have demonstrated a significant relative reduction in mortality in high-risk individuals with low-dose computed tomography screening. However, biomarkers capable of identifying the most at-risk population and detecting lung cancer before it becomes clinically apparent are urgently needed in the clinic. Here, we report the identification of urine biomarkers capable of detecting lung cancer. Using the well-characterized inducible Kras (G12D) mouse model of lung cancer, we identified alterations in the urine proteome in tumor-bearing mice compared with sibling controls. Marked differences at the proteomic level were also detected between the urine of patients and that of healthy population controls. Importantly, we identified 7 proteins commonly found to be significantly up-regulated in both tumor-bearing mice and patients. In an independent cohort, we showed that 2 of the 7 proteins were up-regulated in urine samples from lung cancer patients but not in those from controls. The kinetics of these proteins correlated with the disease state in the mouse model. These tumor biomarkers could potentially aid in the early detection of lung cancer.Keywords
This publication has 34 references indexed in Scilit:
- Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between Overexpressed Serum Proteins and Non-Small Cell Lung CancerPLOS ONE, 2012
- Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor ModelsCancer Cell, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Clinical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and CarboplatinClinical Cancer Research, 2008
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Randomized controlled trial of screening for hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2004